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Mesenchymal stem cells (MSCs) are multipotent cells able to diﬀerentiate into multiple cell types, including adipocytes, osteoblasts,
and chondrocytes. The role of adipose-derived stem cells (ADSCs) in cancers is signiﬁcantly relevant. They seem to be involved in
the promotion of tumour development and progression and relapse processes. For this reason, investigating the eﬀects of breast
cancer microenvironment on ADSCs is of high importance in order to understand the relationship between tumour cells and
the surrounding stromal cells. With the current study, we aimed to investigate the speciﬁc characteristics of human ADSCs
isolated from the adipose tissue of breast tumour patients. We compared ADSCs obtained from periumbilical fat (PF) of
controls with ADSCs obtained from adipose tissue of breast cancer- (BC-) bearing patients. We analysed the surface antigens
and the adipogenic diﬀerentiation ability of both ADSC populations. C/EBPδ expression was increased in PF and BC ADSCs
induced to diﬀerentiate compared to the control while PPARγ and FABP4 expressions were enhanced only in PF ADSCs.
Conversely, adiponectin expression was reduced in PF-diﬀerentiated ADSCs while it was slightly increased in diﬀerentiated BC
ADSCs. By means of Oil Red O staining, we further observed an impaired diﬀerentiation capability of BC ADSCs. To
investigate this aspect more in depth, we evaluated the eﬀect of selective PPARγ activation and nutritional supplementation on
the diﬀerentiation eﬃciency of BC ADSCs, noting that it was only with a strong diﬀerentiation stimuli that the process took
place. Furthermore, we observed no response in BC ADSCs to the PPARγ inhibitor T0070907, showing an impaired activation
of this receptor in adipose cells surrounding the breast cancer microenvironment. In conclusion, our study shows an impaired
adipogenic diﬀerentiation capability in BC ADSCs. This suggests that the tumour microenvironment plays a key role in the
modulation of the adipose microenvironment located in the surrounding tissue.
1. Introduction
Mesenchymal stem cells (MSCs) are used in regenerative
medicine for the treatment of tissue damage after speciﬁc
pathological processes, such as graft versus host disease,
articular cartilage, and other bone injuries [1]. MSCs can be
eﬃciently derived from diﬀerent tissues such as the bone
marrow, the adipose tissue, the skin, and the muscle [2]. They
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are multipotent cells with the ability to diﬀerentiate into var-
ious cell types, such as adipocytes, osteoblasts, and chondro-
cytes [3]. The adipose tissue is an important endocrine and
metabolic organ characterized by diﬀerent functions, ranging
from hormone secretion to heat production. It contains
diﬀerent cell types such as stromal vascular cells, which
include adipose stem cells (ADSCs), and endothelial progen-
itor cells [4]. ADSCs have proangiogenic, antiapoptotic, anti-
inﬂammatory, and immunomodulatory eﬀects, through
paracrine secretion of cytokines, chemokines, and growth
factors [5, 6]. These functions make them optimal candidates
for cellular therapy in regenerative medicine [7]. Even so,
ADSCs are also involved in promoting tumour development
and progression, as well as relapse processes in diﬀerent
cancer types [8]. Recent studies focused on the interaction
between the stromal resident cells, such as ADSCs, cancer-
associated ﬁbroblasts, and cells deriving from primary
tumour [9]. Several evidences indicate that the cellular
functions associated with invasion and metastasis are not
produced by carcinoma cells, but they are a transient
response to signals that tumour cells receive from their
stromal microenvironment [10, 11]. Indeed, human breast
cancer cells mixed with bone marrow-derived human MSCs,
injected subcutaneously, in a mouse model recruit murine
MSCs and the further circulating human cancer cells, also
stimulating the de novo secretion of the chemokine CCL5.
This suggests that invasion and metastasis of cancer cells
from the primary site are driven by signals released from
the stroma of the primary tumour [10]. Indeed, the interac-
tion of human breast carcinoma cells with bone marrow-
derived human MSCs signiﬁcantly increases metastatic
potency. Moreover, the interaction of cancer cells and MSCs
induces the transformation of MSCs into cancer-associated
ﬁbroblasts through the production of CCL5 and osteopontin,
promoting tumour progression [12].
For these reasons, investigating the eﬀects of breast
cancer (BC) microenvironment on ADSCs could be of cru-
cial importance in order to understand the interaction
between the tumour and its microenvironment. Indeed, it is
known that stromal cells located near the BC microenviron-
ment may develop into mammary carcinogenesis [13]. Inter-
estingly, even if the adipose tissue is the most abundant
stromal constituent in the breast, little is known about the
involvement of resident ADSCs in the BC development. BC
is a frequent carcinoma in postmenopausal women [14]
and is classiﬁed in diﬀerent groups based on the gene expres-
sion proﬁle: luminal A, luminal B, HER2, and basal-like
breast cancer (BLBC) [15]. Increased adiposity and obesity
are associated with an elevated risk of the onset of the most
prevalent form of BC [16]. Clinical experiences have
sustained that BC often develops in close association with
fat [9]; moreover, age is a risk factor, since during the aging
process the mammary tissue becomes richer in fat and less
dense [17]. Adipose tissue can be easily isolated in abundant
quantities from many sites, such as the abdomen and breast
[18]. The adipogenic process conducted by ADSCs is subse-
quent to the activation of PPARγ, the receptor responsible
for the induction of this process [19]. PPARγ’s expression
has been reported to be deregulated in breast cancer patients,
along with other cancer types [20, 21]. Furthermore, multiple
studies are investigating the therapeutic potential of PPARγ
modulators as innovative cancer therapy [22, 23]. The role
that nutrition and especially low- versus high-fat diets play
in breast cancer outcomes becomes even more highlighted
[24–28]. Indeed, studies demonstrated that a low-fat diet is
associated with a signiﬁcant improvement in overall survival
[24]. Multiple protocols use lipid mixtures in in vitro cultures
to mimic a high-fat diet and investigate cellular responses
[29]. Moreover, in murine experimental models, it has been
demonstrated that obesity is associated with increased
survival and persistence of residual tumour cells [26]. Fur-
thermore, dietary fat could modulate the homeostasis of the
adipose tissue acting on processes such as autophagy and
apoptosis [30].
The aim of our study was to investigate whether
ADSCs isolated from the adipose tissue of BC-bearing
patients have speciﬁc cellular and functional characteristics
that may be inﬂuenced, in a bidirectional manner, by the
BC microenvironment and by the tumour itself. Indeed,
there could be diﬀerences in qualitative and quantitative
characteristics of these ADSC populations, in terms of
their adaptation to extended culture and multipotency, or
their response to speciﬁc stimuli, which ultimately relates
to practical considerations regarding also their possible
clinical use.
2. Materials and Methods
2.1. Subjects. Tissues were isolated within the Surgery Unit of
San Paolo Hospital. Patients gave their informed consent
according to the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Milan of
San Paolo Hospital (n. 11698; July 06, 2016). The study
participants were 20 female patients with breast cancer
(BC; Table 1) and 8 women who underwent surgery for
the removal of umbilical hernia or epigastric hernia
(CTRL; periumbilical fat (PF)). All patients enrolled in this
study had a normal BMI (18 5 ≤ BMI ≤ 24 9). In BC
patients, a sample of breast fat was taken 5 cm away from
the cancer lesion. Control fat samples were collected from
the subcutaneous tissue of the abdomen of patients aﬀected
with elective benign, noninﬂammatory, and noninfectious
diseases, namely, umbilical and epigastric hernias. Control
subjects and BC carriers belonged to the same age group
(median 62.3 controls and 63.5 years BC). Subcutaneous
abdominal adipose tissue is rich in stem cells and is com-
monly used for breast lipoﬁlling for its aﬃnity to breast fat.
2.2. Primary Cell Culture. Primary cell cultures, obtained
from PF and from mammary fat of patients with BC, were
cultured following previously published protocols [31].
The cells were cultured in Minimum Essential Media α
medium (MEMα; Invitrogen, Carlsbad, CA, USA) supple-
mented with 15% Fetal Bovine Serum (FBS; JRH Biosci-
ence, Lenexa, KS, USA) and incubated at 37°C in 5%
CO2. After 15 days, the medium and the tissues were
removed and adherent cells were maintained in culture.
The medium was changed every 3 days until the cells
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reached conﬂuence (85%). To avoid spontaneous diﬀeren-
tiation, cells were maintained at a subconﬂuent culture
level. When the cells reached 85% conﬂuence, they were
detached with 0.05% trypsin/EDTA solution (Thermo
Fisher), collected by centrifugation (1200 rpm × 5 min)
and expanded in culture or cryopreserved at −80°C in
the presence of dimethyl sulfoxide (DMSO; 10%, FBS
90%). All in vitro experiments were performed in 5 isolates
of each group (PF ADSCs and BC ADSCs) with similar
results. All reported images are representatives of what was
observed in the 5 isolates. Immunoﬂuorescence and Oil
Red O quantiﬁcations were determined as the mean of 3
ﬁelds/isolate for 5 isolates.
2.3. Proliferation. Cellular proliferation was analysed by
cumulative population doubling (CPD). Cells were plated at
a density of 7000 cells/cm2 and counted by using trypan blue
(Life Technologies, Gaithersburg, MD) at 85% conﬂuence.
Curves were obtained calculating the population doubling
(PD) with the following:
PD = log10NH − log10NSlog102
, 1
where NS is the cell number at seeding (7000 cells/cm2) and
NH is the cell number at harvest. To calculate the CPD, the
PD determined for each passage is then added to the CPD
of the previous passage. Cells were incubated for 5min with
0.1% trypan blue (Life Technologies, Gaithersburg, MD),
examined by light microscopy with a minimum of 100 total
cells counted per slide, and scored as able (live) or unable
to exclude the dye (apoptotic).
2.4. Immunophenotypic Characterization. Cultures of PF
ADSCs and BC ADSCs at diﬀerent passages (lower than pas-
sage 4) were phenotypically characterized following reference
guidelines [32, 33]. ADSCs obtained from PF- or BC-bearing
patients were detached with 0.05% trypsin/EDTA (Thermo
Fisher), washed with PBS, and 100000 cells were resuspended
in 250 μL of PBS without Ca2+ and Mg+ (Euroclone, Pero,
Italy) and incubated with antibodies directed against speciﬁc
surface markers. Cells were incubated on ice for 30 minutes
with antibodies anti-CD44 (BD Biosciences, San Jose, CA),
anti-CD90 (Millipore, Massachusetts, USA), anti-CD34
(Miltenyi Biotec, Calderara di Reno, BO, Italy), anti-CD45
(BD Biosciences), anti-CD146 (Biocytex, USA), anti-CD31
(Miltenyi Biotec), anti-CD56 (Miltenyi Biotec), anti-CD105
(Serotec, Bio-Rad, Segrate, MI, Italy), anti-CD144 (R&D
Systems, Minneapolis, MN, USA), anti-CD166 (BD Biosci-
ences), anti-CD133/2 (Miltenyi Biotec), anti-CD73 (BD Bio-
sciences), and anti-vascular endothelial growth factor 2
(VEGFR2; R&D Systems). Cells were pelleted, washed, and
ﬁxed in 4% paraformaldehyde (Sigma-Aldrich) for 20
minutes. Fluorescence-activated cell sorting (FACS) analysis
was performed on a FACSVerse ﬂow cytometer (BD Biosci-
ences), equipped with the Cell Sweet software for data
analysis.
Table 1: Clinical characteristics of the 20 breast cancer-aﬀected patients enrolled in the present study.
N Age Histology Grading ER PR Ki67 (%) Her2/neu TNM Stage Operation
1 56 LIC G2 + + 10 - pT1b, N0(sn) IA QDR+SNB
2 69 DIC G2 + + 25 - pT1b, Nx IA QDR
3 75 DIC G2 + - 8 + pT1c, N1mi(sn) IB QDR+SNB
4 82 DIC G3 + - 35 + pT2, pN1a IIB QDR+AND
5 54 DIC G3 + - 25 + pT1c, pN0(sn) IA QDR+SNB
6 48 DIC G2 + + 40 + pT2, N1a IIB QDR+AND
7 63 DIC G3 + + 25 + pT1c, N0(sn) IA QDR+SNB
8 66 DIC G2 + + 10 - pT1b, N0(sn) IA QDR+SNB
9 64 DIC G2 + + 8 + pT1c, pN0(sn) IA QDR+SNB
10 78 DIC G2 + + 12 + pT1c, pN0(sn) IA QDR+SNB
11 47 DIC∗ G2 + + 8 + pT1c, pN1mi IB QDR+SNB
12 69 DIC G2 + + 15 - pT1c, pN0(sn) IA QDR+SNB
13 44 DIC G1 + + 12 + pT1c, pN1mi IB QDR+SNB
14 52 DIC G3 - - 85 - pT1c, pN1a IIA QDR+AND
15 66 DIC G2 + + 18 + pT2, pN0(sn) IIA QDR+SNB
16 58 LIC G2 + + 10 - pT2, pN3a IIIC QDR+AND
17 68 DIC G1 + + 5 + pT1b, pN0(sn) IA QDR+SNB
18 76 DIC G3 + + 55 + pT2, pN1a(sn) IIB QDR+AND
19 65 DIC G2 + + 12 + pT1b, pN0(sn) IA QDR+SNB
20 63 LIC G2 + + 10 + pT2, pN1mi(sn) IIB QDR+SNB
ER: estrogen receptors; PR: progesterone receptors; TNM: according to AJCC (American Joint Committee on Cancer)/UICC (Union for International Cancer
Control) classiﬁcation: release 2017; LIC: lobular inﬁltrating carcinoma; DIC: ductal inﬁltrating carcinoma; DIC∗: ductal inﬁltrating carcinoma, papillary
variant; QDR: standard quadrantectomy; SNB: sentinel node biopsy; AND: axillary node dissection; sn: sentinel node; mi: node micrometastasis.
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2.5. Immunoﬂuorescence Staining. After seeding and diﬀer-
entiation (3500 cells/cm2) onto glass slides, cells were grown
until 85% conﬂuence. They were then ﬁxed with 4% parafor-
maldehyde (Sigma-Aldrich). After saturation and perme-
abilization (4% BSA (Sigma-Aldrich), 0.3% Triton X-100
(VWR International, Radnor, PA, USA)), cells were incu-
bated overnight at 4°C with primary antibodies against
PPARγ (1 : 100; Cell Signaling Technology, Beverly, MA,
USA), C/EBPβ (1 : 100; Cell Signaling Technology), C/EBPδ
(1 : 100 Santa Cruz, Dallas, TX, USA), FABP4 (1 : 100 Cell
Signaling Technology), leptin R (1 : 100; Abcam, Cambridge,
UK), and adiponectin (1 : 100 Abcam). Cells were rinsed and
then probed for 45 minutes with secondary antibody Alexa
Fluor 488 (Invitrogen, Carlsbad, CA, USA). Nuclei were
counterstained with DAPI (2 μg/mL in PBS; Sigma-Aldrich),
and glasses were mounted with FluorSave™ (Millipore).
Images were taken using a Leica SP2 confocal microscope
with He/Kr and Ar lasers (Heidelberg, Germany). In negative
control experiments, primary antibodies were replaced with
equivalent concentrations of unrelated IgG of the same
subclass. The quantiﬁcation of positive cells was performed
by considering a minimum of nine independent ﬁelds (three
ﬁelds/three coverslips/treatment) captured with a 20x objec-
tive. The number of positive cells was expressed as the
percentage to the total cell number given by DAPI nuclear
staining.
2.6. Adipogenic Diﬀerentiation and Oil Red O Staining. PF
and BC ADSCs were seeded (6000 cells/cm2) in adipogenic
medium consisting of DMEM high glucose (Euroclone, MI,
Italy) supplemented with 10% FBS, 1 μmol/L dexamethasone
(Sigma-Aldrich, St. Louis, MO, USA), 0.5mM 3-isobutyl-1-
methyl-xanthine (Sigma-Aldrich), and 10 μM insulin
(Sigma-Aldrich) [34, 35]. Alternatively, BC ADSCs were also
diﬀerentiated with standard adipogenic medium supple-
mented with 1 μg/mL troglitazone (Sigma-Aldrich), a potent
PPARγ activator [36, 37], or with a 10% lipid mixture
(Sigma-Aldrich) in order to mimic a high-fat diet [29]. The
ﬁnal lipidic concentration in this last reagent was thus
200ng/mL arachidonic acid; 1μg/mL linoleic, linolenic, myr-
istic, oleic, palmitic, and stearic acids; 22μg/mL cholesterol;
and 7μg/mL tocopherol acetate. The diﬀerentiation potential
was assessed also after the supplementation with the potent
and selective PPARγ antagonist T0070907 (1 μM) [38]. After
7 days in culture, a suﬃcient time for adipocyte diﬀerentia-
tion and lipid droplet formation [39–41], cells were ﬁxed in
4% formaldehyde for 1 h and stained with Oil Red O
(Sigma-Aldrich). Total counts of positive cells were per-
formed, and the number of positive cells was expressed as
the percentage to the total cells. To quantify the intracellular
lipid accumulation of Oil Red O, the stained lipid droplets
were eluted with 100% isopropanol for 10min. The optical
density was measured at 520nm by a spectrophotometer
[41]. These evaluations were performed by means of the soft-
ware ImageJ (NIH).
2.7. RNA Extraction and Real-Time PCR. For gene expression
analysis, cells were plated at a density of 6000 cells/cm2 and
induced to diﬀerentiate for 7 days. Total RNA was extracted
using a TRIZOL® reagent (Life Technologies) following
the manufacturer’s instructions and then quantiﬁed
(NanoPhotometer® NP80, Implen). Total RNA (1 μg)
was reverse transcribed using an iScript cDNA synthesis
kit (Bio-Rad) according to the manufacturer’s instructions.
Real-Time PCR was performed with the StepOnePlus™
Real-Time RT-PCR System (Thermo Fisher) using iQ SYBR
Green Supermix (Bio-Rad). Primers were designed using the
NCBI’s Primer-BLAST and are listed in Supplementary
Table 1. Gene expression was calculated using the 2-ΔΔCt
method, and GAPDH was used as a housekeeping gene.
2.8. Statistics. Results are expressed as the means ± SD and
analysed using GraphPad Prism software (version 5.0,
GraphPad Software, San Diego, California). Two-tailed
unpaired Student’s t-test was used to analyse normally dis-
tributed data. When three or more value sets were com-
pared, one-way ANOVA was used followed by Tukey’s
posttest applied. The statistical signiﬁcance was accepted
for a p value < 0.05.
3. Results
3.1. Proliferation. BC ADSC and PF ADSC proliferation was
studied with cumulative population doubling (CPD) curves
(Figure 1). The cellular proliferative activity gradually
increased with the progression in the number of passages
reaching a plateau at around passage 13 in PF ADSCs and
around passage 16 in BC ADSCs. This indicates that BC
and PF ADSCs have a similar proliferating activity.
3.2. Phenotypic Characterization of PF and BC ADSCs. To
evaluate the phenotypic features of the primary cultures, ﬂow
cytometry analysis of the two cellular populations was
performed. We evaluated the expression of mesenchymal
surface markers (CD73, CD90, and CD105), hematopoietic
markers (CD14, CD45, CD56, and CD133), D-related
human leukocyte antigen (HLA-DR), endothelial markers
(CD31 and CD34), adhesion surface markers (CD144,
CD44, CD146, and CD166), and receptor for vascular endo-
thelial growth factor 2 (VEGFR2 also known as KDR). The
evaluation was performed in triplicate at passage 4 for all
investigated isolates (Supplementary Figure 1). Figure 2
shows the characterization of surface markers restricted to
ﬁve isolates for each group, PF and BC ADSCs, which were
used for all the in vitro experiments. PF and BC ADSCs
strongly express the mesenchymal markers CD73 and
CD105, with similar levels (close to 100%), and CD90,
which is slightly less present in BC ADSCs. Few cells in
both groups were positive to the hematopoietic markers
CD14, CD45, and CD56; to the endothelial markers CD31
and CD34; and to HLA-DR and CD133. The percentage of
cells positive to CD44 was very high (close to 100%), in
both cell types. The adhesion surface marker CD144 and
the receptor for vascular endothelial growth factor 2 (KDR)
were signiﬁcantly more expressed in BC ADSCs. On the
contrary, CD146 and CD166 (adhesion surface markers)
were signiﬁcantly more expressed in PF ADSCs than BC
ADSCs.
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Figure 2: Cell surface phenotype of 5 PF ADSCs (black boxes) and 5 BC ADSCs (red boxes). All percentages were obtained by ﬂow cytometry
analysis. Results were obtained from three independent experiments for each isolate. The statistical signiﬁcance was determined by
Student’s t-test; ∗∗∗∗p < 0 0001, ∗∗p < 0 01, and ∗p < 0 05 vs. PF ADSCs.
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Figure 1: Long-term multipassage cultures of BC ADSCs and PF ADSCs. The graph shows a cumulative population doubling (CPD) across
multiple consecutive passages (mean ± SD; n = 5). The cells were plated at a density of 7000 cell/cm2 and counted in triplicate by trypan blue
exclusion at 85% conﬂuence.
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3.3. Expression of Adipogenic Markers in BC and PF ADSCs.
PF and BC ADSCs were induced to diﬀerentiate with adipo-
genic medium for 7 days and then compared to nondiﬀeren-
tiated cells (cells grown in standard maintenance medium).
After 7 days of adipogenic induction, the expression of diﬀer-
entiation markers was investigated by immunoﬂuorescence
with speciﬁc antibodies. A statistically signiﬁcant increase
of C/EBPδ expression, a marker of preadipocyte stages, was
observed in both PF and BC ADSCs induced to diﬀerentiate
compared to cells grown in control medium (Figures 3(a)
and 3(b)). Localization of C/EBPδ was greatly increased
in the nuclei of both diﬀerentiated ADSCs. Adipogenic
diﬀerentiation caused the increase of PPARγ expression,
an active modulator of lipid metabolism, only in PF
ADSCs. The levels of this factor in BC under adipogenic
stimulation were comparable to control standard culture
conditions (undiﬀerentiated cells). The expression of adipo-
nectin was reduced in PF-diﬀerentiated ADSCs while it was
slightly increased in BC ADSCs induced to diﬀerentiate. Lep-
tin receptor and C/EBPβ expression in PF-diﬀerentiated
ADSCs was decreased compared to the same cells main-
tained in control conditions. No signiﬁcant variation was
found for the leptin receptor and C/EBPβ in BC ADSCs
induced to diﬀerentiate compared to control BC ADSCs.
The levels of FABP4, a regulator of fatty acid, increased in
diﬀerentiated PF ADSCs whereas its expression decreased
in diﬀerentiated BC ADSCs. Together, these results suggest
an impairment in adipogenic diﬀerentiation capabilities of
BC ADSCs compared to PF ADSCs.
To investigate further the possible impairment of BC
ADSC adipogenesis, the eﬃciency of the process was evalu-
ated with Oil Red O staining in order to examine the lipid
droplet formation. Indeed, Oil Red O staining (red colour)
accumulated in lipid droplets in PF ADSCs, indicating a
successful diﬀerentiation (Figures 4(a) and 4(b)). The quanti-
ﬁcation of both Oil Red O-positive cells and optical density
after its extraction was analysed. As expected, PF ADSCs
diﬀerentiated and presented a higher lipid accumulation
compared to the control (Figure 4). More than 45% of diﬀer-
entiated PF ADSCs resulted positive to the Oil Red O
staining. The quantiﬁcation of lipid accumulation obtained
by measuring the absorbance at 520nm after the extraction
procedure conﬁrmed these observations. Interestingly, the
BC ADSCs induced to diﬀerentiate did not present lipid
droplet accumulation, suggesting that the standard adipo-
genic medium is insuﬃcient to ensure successful diﬀerentia-
tion (Figure 4).
3.4. Eﬀect of PPARγ Stimulation and Nutritional
Supplementation on BC ADSC Diﬀerentiation Capabilities.
The observation that BC ADSCs seem to present a diﬀerent
and reduced diﬀerentiation ability compared to PF ADSCs
led us to investigate whether the process can be stimulated
by exogenous factors such as situations when the adipogenic
diﬀerentiation was exacerbated. To do so, we adopted two
diﬀerent diﬀerentiation protocols: the culture medium was
supplemented in the ﬁrst protocol with troglitazone
(1 μg/mL; TRO), a potent PPARγ activator [36, 37], and in
the second one with a lipid mixture of free fatty acids (10%
v/v; FFA), used to mimic a high-fat diet [29]. The rationale
is that there could be an altered PPARγ modulation, in line
with literature reports indicating an alteration in PPARγ
expression in breast cancer cells [20]. Furthermore, we
wished to preliminarily identify a potential mechanism for
the obesity correlation with breast cancer [25–28]. The accu-
mulation of lipid droplets, investigated by Oil Red O staining,
was increased in both conditions, and this is signiﬁcantly
relevant when the lipid mixture was added (Figure 5).
3.5. Eﬀect of PPARγ Pharmacologic Inhibition on BC ADSC
Diﬀerentiation Capabilities. Following the observation that
BC ADSCs seem unresponsive to PPARγ canonical stimula-
tion, we aimed to clarify whether this was true also for the
receptor’s inhibition. The treatment with the potent and
selective PPARγ antagonist T0070907 (1 μM) [38], added
to the medium supplemented with troglitazone or FFA, was
not able to signiﬁcantly counteract the lipid droplet accumu-
lation in BC ADSCs (Figure 6 and Supplementary Figure 2).
Both the extracted Oil Red O and the percentage of
diﬀerentiated cells resulted unaﬀected by the application of
T0070907 (Figure 6 and Supplementary Figure 2). As the
control of the experiments, T0070907, at the same
concentration, was also added to the diﬀerentiating medium
of PF ADSCs. In this control case, the potent inhibitory
eﬀect was appreciable (Figure 6 and Supplementary
Figure 2). The demonstration that T0070907 is eﬀective in
PF ADSCs but leaves BC ADSCs unaﬀected again supports
the idea that these cells are unresponsive to PPARγ
canonical activation.
To conﬁrm the evidences reported above, the expression
of PPARγ was analysed by real-time PCR in order to verify
the molecular changes occurring in the cells during the diﬀer-
entiation process. As expected, in diﬀerentiated PF ADSCs,
PPARγ mRNA was signiﬁcantly increased and, conversely,
resulted downregulated when cells were also treated with
the PPARγ inhibitor (Figure 7). In BC ADSCs, the increase
of the adipogenic master gene was observed only when cells
were supplemented with troglitazone or FFA (Figure 7).
The presence of the inhibitor T007097 did not alter PPARγ
expression in BC ADSCs. This suggests that a protocol mim-
icking nutritional supplementation with a high-fat diet has
the ability to modify the genetic proﬁle and diﬀerentiation
capabilities of BC ADSCs but that this activation is poten-
tially unaﬀected by PPARγ activity.
4. Discussion
This study is aimed at comparing the features of ADSCs iso-
lated from the adipose tissue of breast cancer- (BC-) bearing
patients with ADSCs isolated from PF of cancer-free patients,
considered here controls. The project stems from various
lines of evidences suggesting a role for BC ADSCs during
tumour progression and relapse processes. It has been dem-
onstrated that the interactions between cancer and its local
microenvironment can determine features such as growth,
metastasis, and angiogenesis [11, 12]. Even so, the eﬀects of
MSCs on cancer cells are controversial, with evidences indi-
cating the promotion of metastasis and other inhibitions of
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cancer cell invasion and growth induced by MSCs [42, 43].
The cross-talk between a tumour microenvironment and
cancer cells has been characterized both in animal experi-
mental models [10] and in in vitro MDA-MB-231 cells
[12], demonstrating that the tumour and its microenviron-
ment create an intertwined loop favouring tumour
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Figure 3: Immunoﬂuorescence analysis of ADSC marker expression after 7 days of culture in standard medium (undiﬀerentiated ADSCs)
and in adipogenic diﬀerentiation medium (diﬀerentiated ADSCs). (a) Immunoﬂuorescence assay for C/EBPδ, PPARγ, adiponectin (AD),
leptin receptor (LR), C/EBPβ, and FAB4 (green labelling) which are markers of adipogenesis progression. Nuclei were stained with DAPI
(blue labelling). Negative control isotype staining was performed using normal goat serum in place of the primary antibody. Scale bars:
50 μm. (b) Quantiﬁcation of cell positivity to adipogenic markers. The number of positive cells, expressed as the percentage to the total
cell number given by DAPI nuclear staining, was calculated as an average of 15 diﬀerent ﬁelds for each marker (3 ﬁelds/isolate). Error bars
represent the SEM for three experiments. The statistical signiﬁcance was determined by Student’s t-test; ∗p < 0 05 vs. undiﬀerentiated
ADSCs; ∗∗p < 0 01 vs. undiﬀerentiated ADSCs; ∗∗∗p < 0 001 vs. undiﬀerentiated ADSCs.
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progression. Mesenchymal stem cells can be regulators of this
process, as evidences show their role in promoting breast
cancer metastasis [11]. Further, elucidating the cellular fea-
tures of ADSCs surrounding the tumour microenvironment
could be of crucial importance in the modulation of the
tumour itself.
We observed that in vitro expanded PF and BC ADSCs
displayed diﬀerent characteristics in terms of adipogenic
marker expression and phenotypical features of diﬀerentia-
tion. This is, to our knowledge, the ﬁrst study describing
the phenotypic characterization of PF and BC ADSCs along
with their adipogenic diﬀerentiation. Since during diﬀerenti-
ation the proliferation of BC ADSCs slowed down shortly
with a high rate of mortality (data not shown), 7 days was
considered an adequate time to study the process. MSCs
are known to show negative expression of hematopoietic
surface markers, cluster of diﬀerentiation (CD34, CD45,
and HLA-DR), and endothelial marker (CD31) but high
expressions of CD73, CD90, and CD105 [44]. CD45 is
found in hematopoietic cells and regulates cell growth, diﬀer-
entiation, mitotic cycle, and oncogenic transformation [45].
CD90 is a membrane-bound glycoprotein which is expressed
by almost 90% of variable tissues, and its function is related
to angiogenesis [46]. Consistent with literature reports,
almost all of the PF and BC ADSCs express surface markers
related to MSCs at very high levels (close to 100%) without
any diﬀerence depending of the source, while the endothelial
and hematopoietic markers were detected only in a small
percentage. The slightly lower (but still high) levels of
CD90 expression in BC ADSCs compared to PF ADSCs
might be caused by the high variability between samples.
CD144 (VE-cadherin) is an adhesion protein expressed in
endothelial cells. Molecules associated with angiogenesis
and vasculogenesis, including this marker, are usually found
strongly upregulated in aggressive cancers [47, 48], consis-
tent with our observations. CD146, a typical adhesion
marker, is reported as a common surface marker of MSCs,
and the activation of CD146 induces the dynamic process
of dimerization in response to stimuli in a tumour micro-
environment [49]. Indeed, the biological signiﬁcance of
CD146 in a normal tissue remains unclear, even if it has
been suggested to have a fundamental role in cancer,
angiogenesis, and cardiovascular diseases [50]. It has been
reported that the surface markers such as CD133, in com-
bination with CD29/CD24 and CD44/CD166, may corre-
late with high Wnt activity and identify stem cells in
various tumour types and their possible interaction with
the microenvironment [51]. Interestingly, in BC ADSCs,
the markers CD144, CD146, CD166, and KDR result sig-
niﬁcantly deregulated suggesting oncogenic alteration also
in the tumour microenvironment with a possible role in
favouring angiogenesis, tumour cell migration, and prolif-
eration [52].
Adipogenic diﬀerentiation is regulated by a complex
network of transcription factors. It begins with increased
expressions of CCAT/enhancer-binding protein (C/EBP),
which in turn activate peroxisome proliferator-activated
receptor γ (PPARγ) [53]. In mammalian cells, the PPARγ
and the C/EBPs such as C/EBPα, C/EBPβ, and C/EBPδ are
considered the key early regulators of adipogenesis, while
fatty acid-binding protein 4 (FABP4), adiponectin, and fatty
acid synthase (FAS) are responsible for the formation of
mature adipocytes [54]. It is reported that FABP4 is an
adipokine with a distinct role of transcriptional and meta-
bolic regulation in ASCs [55]. FABP4 is increased during
the diﬀerentiation only in PF ADSCs, and interestingly, its
expression decreases when BC ADSCs are induced to diﬀer-
entiate. PF ADSCs show a signiﬁcant increase of PPARγ
during the adipogenic diﬀerentiation, in accordance with
other works stating that PPARγ is directly associated with
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Figure 4: Adipogenesis was revealed by Oil Red O staining for lipid droplet accumulation. (a) Representative images of PF ADSCs and BC
ADSCs in control conditions and after adipogenic diﬀerentiation for 7 days (diﬀerentiated ADSCs). Scale bars: 200 μm. Data are
representatives of ﬁve diﬀerent isolates. (b) Magniﬁcations of (a) images of PF ADSCs and BC ADSCs in control conditions and after
adipogenic diﬀerentiation for 7 days (diﬀerentiated ADSCs). Accumulation of lipid droplets, stained with Oil Red O, is highlighted with
red arrows. Scale bars: 100μm. Data are representatives of ﬁve diﬀerent isolates. (c) Percentage of cells positive to Oil Red O staining and
quantiﬁcation of Oil Red O extracted from lipid droplets measured at 520 nm normalized over nucleus counts. Data are reported as the
mean ± SD of 5 diﬀerent isolates. The statistical signiﬁcance was determined by Student’s t-test; ∗∗∗∗p < 0 0001 and ∗p < 0 05 vs. UNDIFF
PF ADSCs.
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lipid metabolism. On the other hand, in BC ADSCs
induced to diﬀerentiate, PPARγ does not show a signiﬁcant
diﬀerence with the undiﬀerentiated cells. This is conﬁrmed
with multiple techniques, observing a phenotypic (immu-
nohistochemistry) and genetic (real-time PCR) incapability
of these cells to express the PPARγ receptor and thus eﬃ-
ciently diﬀerentiate. Indeed, BC ADSCs show an impaired
ability compared to PF ADSCs to diﬀerentiate into adipo-
cytes. At this stage of diﬀerentiation, no diﬀerences were
observed for C/EBPβ while C/EBPδ was increased in both
cellular populations, as expected.
The observations indicating an impaired diﬀerentiation
ability of BC ADSCs, together with literature reports describ-
ing PPARγ deregulation in breast cancer patients and its
possible role as a therapeutic target [20–23], lead us to further
investigate the role that this receptor could play in BC
ADSC diﬀerentiation. To this end, we attempted to stimu-
late BC ADSC diﬀerentiation with the supplementation of
the PPARγ activator troglitazone [37]. We found that this
slightly increases BC ADSC adipogenic diﬀerentiation but
that this increase is not impaired following the supplemen-
tation with the PPARγ inhibitor T007097, supporting the
claim that BC ADSCs are partially insensitive to PPARγ
modulation. We hypothesise that troglitazone could also
mediate PPARγ-independent eﬀects on BC ADSCs but
the identiﬁcation of a speciﬁc activated pathway would
require further analysis. Interestingly, previous literature
reports demonstrate that troglitazone inhibited telomerase
activity in MDA-MB-231 cells, independently of PPARγ
activity [56].
Moreover, we decided to investigate the concept that
nutrients and obesity may have in BC progression [9, 16],
evaluating the eﬀects of a high-fat diet on the diﬀerentia-
tion properties of BC ADSCs. The aim was to gain more
in depth insight into epidemiologic and experimental
evidences suggesting the role of nutritional health and
high/low-fat diets in the regulation of breast cancer prog-
nosis [16, 24–28]. The results obtained were very interest-
ing, demonstrating a signiﬁcant lipid accumulation and
also a signiﬁcant increase in PPARγ expression. This
observation could support the evidences that nutrition
inﬂuences the breast cancer microenvironment, and target-
ing this pathway may be of key importance in modulating
tumour progression. In the experimental context of BC
ADSCs, the PPARγ inhibitor T007097 was proved ineﬃ-
cient in modulating BC ADSC adipogenesis after lipid
mixture supplementation.
Together, these results indicate that BF ADSCs are
unable to diﬀerentiate when stimulated with a standard
protocol, but this can be partially overcome by supplement-
ing the diﬀerentiation medium with troglitazone or FFA.
The demonstration that BC ADSCs were proved unrespon-
sive to the PPARγ inhibitor T007097 further supports the
hypothesis that this receptorial signalling is partially
impaired in these cells, although further experimental analy-
ses are required to elucidate the speciﬁc intracellular path-
ways activated.
5. Conclusions
In conclusion, this study shows that there is a signiﬁcant
diﬀerence between healthy fat tissue and fat tissue of BC-
bearing patients when observing molecular marker expres-
sion, phenotype, and adipogenic diﬀerentiation capability.
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Figure 5: Eﬀect of PPARγ activation and FFA supplementation on BC ADSC diﬀerentiation. (a) Adipogenesis was revealed by Oil Red O
staining for lipid droplets. (a) shows representative images of BC ADSCs in control conditions and after adipogenic diﬀerentiation for 7
days with three diﬀerent protocols (diﬀerentiated BC ADSCs, diﬀerentiated BC ADSCs with troglitazone, and diﬀerentiated BC ADSCs
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Indeed, BC ADSCs present with an impaired diﬀerentia-
tion eﬃciency. The present study also shows some prelim-
inary, although very interesting, results correlating the role
of nutrition on a tumourigenic microenvironment, but
more studies are necessary to elucidate the precise mecha-
nisms. Furthermore, the observation of BC ADSC
unresponsiveness to PPARγ canonical stimulation and
inhibition could provide evidence of new deregulated and
targetable cancer pathways. This is the ﬁrst study that
characterizes ADSCs from fat tissue near the breast cancer
and compares them with ADSCs derived from periumbili-
cal fat. Furthermore, for the ﬁrst time, the adipogenic
diﬀerentiation potential of BC ADSCs was studied. With
these promising results, further studies aiming at clarifying
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the mechanism of adipogenic diﬀerentiation from the BC
microenvironment and its role in BC development could
be of crucial importance in the understanding of breast
cancer progression and metastasis.
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